BioNexus Gene Lab (BGLC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3.1M

Revenue (quarter)

$76,156.00

Revenue growth (year over year)

−96.63%

Gross profit (trailing twelve months)

$385,894.00

Gross margin

12.34%

Net income (trailing twelve months)

−$2.6M

Net income (quarter)

−$286,451.00

Net income growth (year over year)

+53.51%

Net margin

−82.36%

Return on equity

−33.66%

EPS (trailing twelve months)

−$1.26

Book value per share

$3.22

P/E (trailing twelve months)

—

Price to book

0.49

Debt to assets

10.86%

Payout ratio

—

Dividend yield

—

Company profile

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

• Is BioNexus Gene Lab (BGLC) profitable?

  No. BioNexus Gene Lab reported a net loss of $2.6M over the trailing twelve months.

• How much revenue does BioNexus Gene Lab (BGLC) make?

  BioNexus Gene Lab generated $3.1M in revenue over the trailing twelve months, down 96.63% year over year.

• How do I buy stock in BioNexus Gene Lab (BGLC)?

  BGLC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.